Targeted Treatment of Metastatic Triple-Negative Breast Cancer: A Systematic Review
Introduction. Triple-negative breast cancer (TNBC) is a subgroup of breast cancer characterized by the absence of estrogen and the human epidermal 2 receptor and also a lack of targeted therapy options. Chemotherapy has so far been the only approved treatment option, and patients with metastatic can...
Saved in:
| Main Authors: | Anna Martha Hammershøi Madsen, Rikke Helene Løvendahl Eefsen, Dorte Nielsen, Iben Kümler |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | The Breast Journal |
| Online Access: | http://dx.doi.org/10.1155/2024/9083055 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review
by: Emilie Adrian Christiansen, et al.
Published: (2024-12-01) -
Metastatic Triple Negative Breast Cancer: The New Era of Thinking
by: Mohammed Amrallah A., et al.
Published: (2021-05-01) -
Targeting TUBB2B inhibits triple-negative breast cancer growth and brain-metastatic colonization
by: Qingling He, et al.
Published: (2025-02-01) -
Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?
by: M. E. Cazzaniga, et al.
Published: (2017-01-01) -
Clinical case of torpid course of metastatic triple negative breast cancer
by: E. P. Kulikov, et al.
Published: (2022-03-01)